Hester Biosciences Ltd 11 Mar 2026 12:00 AM
Hester Biosciences to divest stake in Texas Lifesciences,
The board of Hester Biosciences at its meeting held on 11 March 2026 has approved the divestment of 43.81% equity stake out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL for a consideration of Rs 9.2 crore. TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above. Hester will continue to do business with TLPL and maintain an 11% equity stake/investment in the company. Powered by Capital Market - Live News
Hester Biosciences Ltd 30 Jan 2026 12:00 AM
Hester Biosciences consolidated net profit declines 24.79% in the December 2025 quarter,
Net profit of Hester Biosciences declined 24.79% to Rs 8.77 crore in the quarter ended December 2025 as against Rs 11.66 crore during the previous quarter ended December 2024. Sales rose 22.46% to Rs 77.42 crore in the quarter ended December 2025 as against Rs 63.22 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales77.4263.22 22 OPM %22.998.02 - PBDT17.9617.66 2 PBT13.5213.37 1 NP8.7711.66 -25 Powered by Capital Market - Live News
Hester Biosciences Ltd 22 Jan 2026 12:00 AM
Hester Biosciences to announce Quarterly Result,
Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live News
Hester Biosciences Ltd 20 Nov 2025 12:00 AM
Hester Biosciences appoints Ashish Desai as CFO,
Hester Biosciences announced the appointment of Ashish Desai as Chief Financial Officer and Key Managerial Personnel of the Company (categorised as Senior Management Personnel), presently serving as Group Finance Controller will assume the role of Chief Financial Officer of the Company with effect from 20 November 2025.Powered by Capital Market - Live News
Hester Biosciences Ltd 12 Nov 2025 12:00 AM
Hester Biosciences consolidated net profit rises 76.22% in the September 2025 quarter,
Net profit of Hester Biosciences rose 76.22% to Rs 14.45 crore in the quarter ended September 2025 as against Rs 8.20 crore during the previous quarter ended September 2024. Sales declined 15.20% to Rs 70.97 crore in the quarter ended September 2025 as against Rs 83.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales70.9783.69 -15 OPM %16.5122.89 - PBDT21.3916.07 33 PBT17.0411.87 44 NP14.458.20 76 Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now